List of Excipients in Branded Drug ERYTHROMYCIN LACTOBIONATE

« Back to Dashboard

Generic Drugs Containing ERYTHROMYCIN LACTOBIONATE

Company	Ingredient	NDC	Excipient
Nexus Pharmaceuticals LLC	erythromycin lactobionate	14789-116	WATER
Exela Pharma Sciences LLC	erythromycin lactobionate	51754-7000	WATER
Gland Pharma Limited	erythromycin lactobionate	68083-513	WATER

What are the Most Frequently-Used Excipients in ERYTHROMYCIN LACTOBIONATE?

# Of NDCs	Excipient
3	WATER

Erythromycin Lactobionate Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 30, 2026

Erythromycin lactobionate is an injectable, water-soluble salt of erythromycin used primarily when oral administration is impractical. Its commercial opportunity is concentrated in hospital and emergency-care settings, where a preservative-free, ready-to-reconstitute intravenous macrolide can address supply gaps and patients unable to tolerate oral therapy. The core active ingredient is old and generic. The strongest product opportunities are therefore based on manufacturing reliability, reconstitution performance, container closure, supply continuity, and hospital procurement rather than new-molecule exclusivity.

What is erythromycin lactobionate?

Erythromycin lactobionate is the lactobionate salt of erythromycin, a macrolide antibacterial. The injectable product is supplied as a sterile lyophilized powder for intravenous administration. The salt improves water solubility compared with erythromycin base, allowing parenteral use.

The FDA-approved product labeling identifies erythromycin lactobionate for treatment of susceptible infections, including respiratory tract infections, skin and skin-structure infections, and other infections in patients who require intravenous therapy.[1] The product is generally administered after reconstitution and dilution by intravenous infusion.

Key product characteristics

Attribute	Commercial relevance
Active ingredient	Erythromycin lactobionate
Drug class	Macrolide antibacterial
Dosage form	Sterile lyophilized injectable powder
Route	Intravenous infusion
Typical vial strength	500 mg erythromycin activity per vial
Administration	Reconstituted, diluted, and infused
Preservative profile	Usually preservative-free single-dose presentation
Primary customers	Hospitals, emergency departments, wholesalers, group purchasing organizations
Regulatory pathway	Abbreviated New Drug Application for a therapeutically equivalent generic product
Biosimilar exposure	None; erythromycin is a small-molecule drug

The formulation challenge is driven by erythromycin’s chemical instability, limited aqueous stability, pH sensitivity, and the need to preserve sterility during manufacturing and administration.

What excipients are used in erythromycin lactobionate injection?

The principal formulation component is erythromycin lactobionate itself. Commercial injectable products generally avoid conventional antimicrobial preservatives because the product is supplied as a sterile single-dose powder for reconstitution.

The label directs reconstitution with compatible sterile diluents, including sterile water for injection and selected dextrose or sodium chloride solutions, depending on the product and concentration.[1] The final solution must meet requirements for clarity, potency, particulate control, pH, sterility, and infusion compatibility.

Excipient functions

Excipient or formulation component	Primary function	Strategic issue
Lactobionate counterion	Converts erythromycin into a water-soluble salt	Must maintain potency and acceptable solubility
Sodium hydroxide or acid-adjusting agent, where used	pH adjustment during manufacture	Can affect degradation rate and reconstitution behavior
Sterile water for injection	Reconstitution diluent	Must support rapid dissolution and low particulate levels
Sodium chloride injection	Diluent for administration	Compatibility and concentration limits require validation
Dextrose injection	Alternative infusion diluent	Chemical and physical compatibility must be demonstrated
Nitrogen or controlled headspace, where used	Limits oxidative stress	May improve stability of the lyophilized cake
Stopper and vial system	Maintains sterility and protects the powder	Extractables, leachables, and container integrity are material risks

A generic developer should not treat the inactive ingredient list as the entire formulation strategy. For an injectable product, the manufacturing process, lyophilization cycle, residual moisture, stopper performance, reconstitution time, particulate profile, and in-use stability can be as commercially important as the excipient selection.

What excipient strategy is most attractive for a generic product?

The lowest-risk strategy is a simple, preservative-free, lyophilized formulation that closely follows the reference product’s dosage form, strength, route, and reconstitution instructions. A materially different excipient system could increase development time and regulatory risk without creating a meaningful market advantage.

Recommended formulation priorities

1. Optimize the lactobionate salt system

The formulation should maintain the erythromycin lactobionate salt in a physically stable amorphous or crystalline state, depending on the selected process. Salt formation, pH, ionic strength, and drying conditions influence reconstitution and potency.

Critical quality attributes include:

• Assay and related substances
• Reconstitution time
• Solution clarity
• Visible and subvisible particles
• pH after reconstitution
• Residual moisture
• Cake appearance and collapse temperature
• Sterility and bacterial endotoxins
• Container closure integrity

2. Minimize unnecessary excipients

A short inactive ingredient list can simplify regulatory review and hospital acceptance. It also reduces the risk of incompatibility, extractables, and unexpected degradation.

A formulation with no antimicrobial preservative is commercially preferable for a single-dose injectable product unless the reference product or proposed presentation requires otherwise.

3. Control residual moisture

Residual water in the lyophilized cake can accelerate hydrolysis and other degradation pathways. The lyophilization cycle should be developed around the collapse temperature and glass-transition behavior of the formulation.

A developer should establish:

• Primary drying endpoint
• Secondary drying temperature
• Residual moisture target
• Long-term stability at labeled storage conditions
• Excursion stability during distribution

4. Improve reconstitution performance

Hospitals value fast and predictable reconstitution. Commercial differentiation can come from reducing foaming, clumping, incomplete dissolution, and operator handling steps.

Potential development targets include:

• Shorter reconstitution time
• Lower withdrawal force
• Reduced vial overfill
• Clearer solution appearance
• Fewer required dilutions
• Better compatibility with automated pharmacy compounding systems

These improvements can be protected through process or formulation claims, although practical patent value depends on whether the claims cover a material product distinction and can survive obviousness challenges.

What FDA regulatory pathway applies to erythromycin lactobionate?

A generic erythromycin lactobionate injection would ordinarily be developed under Section 505(j) of the Federal Food, Drug, and Cosmetic Act through an ANDA. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA requirements for injectable products.[2]

For an injectable solution or powder for reconstitution, the regulatory package typically focuses on:

• Same active ingredient
• Same strength
• Same dosage form
• Same route of administration
• Equivalent quality and performance
• Sterility assurance
• Container closure integrity
• Stability
• Inactive ingredient justification
• Labeling consistent with the reference product

The FDA may require additional information if the proposed excipient composition differs from the reference product, particularly when the change affects safety, administration, reconstitution, or compatibility.

What is the Orange Book status of erythromycin lactobionate?

The Orange Book is the controlling source for current listed drugs, reference products, therapeutic equivalence evaluations, patents, and exclusivity information.[3] Erythromycin lactobionate should be assessed by specific reference product, dosage form, strength, and NDA number rather than by the broader erythromycin molecule.

The practical patent conclusion is that the original erythromycin composition and injectable-salt inventions are historically old. A new entrant is more likely to face regulatory and manufacturing barriers than a live, foundational compound patent.

What patents protect erythromycin lactobionate?

The core erythromycin molecule and early erythromycin salt technologies date from the mid-20th century. Those foundational patents have expired. Any currently relevant patent risk would more likely arise from:

• A specific formulation
• A lyophilization process
• A container closure system
• A manufacturing method
• A reconstitution or administration system
• A combination product
• A method-of-use claim

The reference injectable product should be checked in the current FDA Orange Book for listed patents. If no unexpired patent is listed against the applicable reference product, an ANDA applicant would generally not need a Paragraph IV certification for that product, although other certifications and regulatory requirements would still apply.

How many patents cover erythromycin lactobionate?

There is no commercially meaningful basis to count every historical erythromycin patent as a current barrier. The relevant number is the set of unexpired patents listed for the specific reference product and dosage form.

Patent category	Likely status for an old erythromycin injectable
Core erythromycin compound	Expired
Early erythromycin salts	Generally expired
Basic injectable formulation	Generally expired or no longer commercially controlling
Lyophilization process	Potentially relevant if recently claimed
Container closure or device	Potentially relevant
Method of treatment	Potentially relevant but often narrower
Product-specific Orange Book patents	Must be checked against the current reference product

Patent clearance should therefore focus on active, product-linked rights, not the full historical erythromycin patent family.

When does erythromycin lactobionate lose exclusivity?

Erythromycin lactobionate has already lost foundational market exclusivity. The drug is a legacy small-molecule product with multiple historical generic and branded formulations.

The commercial loss of exclusivity occurred decades ago through expiration of the original compound and formulation patents. Any remaining market protection would need to arise from a later product-specific patent, regulatory exclusivity, supply agreement, or practical manufacturing constraint.

There is no biosimilar pathway because erythromycin lactobionate is not a biologic. Competition would come from generic injectable erythromycin products and from therapeutic alternatives such as azithromycin, clarithromycin, clindamycin, and beta-lactam antibiotics.

Are there Paragraph IV challenges for erythromycin lactobionate?

Paragraph IV litigation is relevant only when an ANDA applicant challenges an unexpired patent listed in the Orange Book for the reference product. For an old erythromycin lactobionate injection, the probability of a major current Paragraph IV dispute is low unless a later patent has been listed for a specific formulation, delivery system, or method of use.

An applicant may instead rely on:

• Paragraph I certification if no patent information is listed
• Paragraph II certification if all listed patents have expired
• Paragraph III certification if marketing is deferred until patent expiration
• Paragraph IV certification if a listed patent is invalid, unenforceable, or not infringed

No current blockbuster-scale patent litigation is associated with the active ingredient itself. Product-specific litigation risk remains dependent on the current Orange Book record and any unlisted process or contract rights.

What formulation patents could create commercial differentiation?

The most defensible intellectual-property opportunities would involve a measurable technical improvement rather than simple substitution of common excipients.

Potential claim areas include:

Low-moisture lyophilized cake

Claims could target a defined residual-moisture range, stabilizing excipient ratio, or drying cycle that preserves potency during long-term storage.

Rapid-reconstitution formulation

A formulation that dissolves within a specified time at a defined diluent volume could support process or composition claims. The claim must provide a technical effect beyond routine optimization.

Reduced particulate formulation

Reduced visible and subvisible particles could improve hospital handling and reduce batch rejection. Patentability would depend on the formulation and process, not merely the result.

Improved container closure

A vial, stopper, or crimp system that reduces moisture ingress or extractables could support device or packaging protection.

Ready-to-use or premixed presentation

A premixed erythromycin lactobionate infusion could improve workflow, but it would face higher stability, container, shipping, and microbiological-control requirements than a lyophilized vial.

What manufacturing and IP barriers affect market entry?

The principal barriers are operational.

Sterile manufacturing

The product requires validated aseptic processing or terminal sterilization where feasible. A sterile lyophilized injectable has higher capital and quality-system requirements than an oral solid dosage form.

Lyophilization capacity

Access to qualified lyophilization capacity can limit launch timing. Cycle development, scale-up, loading patterns, and vial heat transfer must be validated.

Stability

The product must maintain potency and impurity limits through labeled shelf life. Erythromycin degradation can create a meaningful development burden, especially under elevated temperature and humidity.

Supply of pharmaceutical-grade starting materials

Reliable erythromycin base, lactobionic acid or the relevant salt-forming inputs, sterile vials, elastomeric closures, and secondary packaging are necessary to avoid supply interruptions.

Hospital procurement

Hospitals often select injectable antibiotics through contracts, group purchasing organizations, and wholesaler channels. A lower price alone may not displace an incumbent supplier if the new product has uncertain availability or limited back-up inventory.

Which companies are challenging erythromycin lactobionate?

Competition is likely to come from established generic injectable manufacturers and contract manufacturers rather than branded innovator companies. Relevant competitive groups include:

• Large generic injectable suppliers
• Hospital-focused pharmaceutical companies
• Contract development and manufacturing organizations
• Regional suppliers with sterile manufacturing capacity
• Distributors offering shortage-driven sourcing

The competitive advantage will depend on FDA approval, product availability, contract pricing, back-order performance, and the ability to supply multiple vial strengths or related erythromycin products.

How does erythromycin lactobionate compare with azithromycin injection?

Factor	Erythromycin lactobionate	Azithromycin injection
Drug class	Macrolide	Macrolide
Formulation	Injectable salt, usually lyophilized	Injectable formulation, commonly supplied as powder for reconstitution
Market age	Older	Newer
Generic competition	Mature	Mature
Clinical role	Alternative IV macrolide where appropriate	Commonly used for selected respiratory and other infections
Patent strength	Foundational rights expired	Foundational rights expired; product-specific rights depend on product
Commercial opportunity	Niche, shortage and formulary driven	Larger established hospital market
Differentiation	Supply reliability and reconstitution	Cost, availability, and clinical familiarity

Azithromycin generally presents the stronger commercial platform because of broader contemporary hospital use. Erythromycin lactobionate can still support a niche strategy where clinicians value the established product, formulary inclusion, or macrolide coverage in patients unable to take oral therapy.

What licensing deals could support erythromycin lactobionate?

A licensing transaction would most likely involve manufacturing or commercialization rights rather than a novel active-ingredient license. Relevant structures include:

• Exclusive regional commercialization rights
• Contract manufacturing with a sterile injectable producer
• Co-development of a ready-to-use presentation
• Supply agreements with hospital distributors
• Portfolio licensing that combines erythromycin lactobionate with other injectable antibiotics
• Technology licensing for lyophilization, packaging, or reconstitution

The strongest deal rationale would be a platform arrangement covering multiple hospital injectables. A stand-alone erythromycin lactobionate license is less likely to command substantial value because the active ingredient has no meaningful composition exclusivity.

What is the revenue exposure and generic launch opportunity?

Erythromycin lactobionate is a niche hospital product rather than a high-growth branded medicine. Product-specific revenue is not reliably disclosed by most suppliers because it is usually included within broader injectable or anti-infective portfolios.

A commercial launch can still be attractive when one or more of the following conditions exist:

1. The market has recurring shortages.
2. The reference supplier has limited manufacturing capacity.
3. Hospitals require a second source.
4. The generic applicant can offer reliable delivery.
5. The product is bundled with other hospital injectables.
6. The manufacturer has excess lyophilization capacity.
7. The applicant can supply multiple regions under aligned regulatory approvals.

The most credible launch model is a low-cost, high-reliability product with disciplined inventory management. A premium price requires a tangible advantage, such as ready-to-use dosing, reduced pharmacy labor, or materially better shelf life.

What generic launch risks exist?

Risk	Commercial effect	Mitigation
Low market size	Limits return on sterile-manufacturing investment	Use shared injectable platform
Price erosion	Reduces gross margin after launch	Secure supply contracts before approval
Manufacturing deviations	Can trigger shortages or recalls	Validate lyophilization and aseptic controls
Reconstitution failures	Creates hospital rejection risk	Optimize cake structure and instructions
Drug shortages	Can increase demand but destabilize procurement	Maintain safety stock
Therapeutic substitution	Limits erythromycin use	Target formularies where the product remains preferred
Regulatory review of excipient differences	Delays approval	Keep formulation close to reference product
Container closure failures	Compromises sterility and shelf life	Use robust vial and stopper qualification

Key Takeaways

• Erythromycin lactobionate is a legacy injectable macrolide with expired foundational exclusivity.
• The principal commercial opportunity is a reliable generic hospital product, not a new molecular-entity strategy.
• A preservative-free lyophilized vial is the lowest-risk formulation platform.
• Lactobionate salt performance, residual moisture, reconstitution time, sterility, and container closure are the main technical priorities.
• Current patent risk is likely to center on product-specific formulation, manufacturing, packaging, or method-of-use claims rather than the erythromycin molecule.
• The product is not subject to biosimilar competition.
• The strongest launch rationale is hospital supply continuity, shortage replacement, and portfolio bundling with other sterile injectables.
• Ready-to-use or rapidly reconstituting presentations could create differentiation but would require additional stability, packaging, and regulatory work.

FAQs

Is erythromycin lactobionate the same as erythromycin base?

No. Erythromycin lactobionate is a salt form designed to improve water solubility for intravenous administration. Erythromycin base is used in other dosage forms and has different formulation properties.

Can erythromycin lactobionate be formulated as a ready-to-use infusion?

Yes, in principle. The product would require validated aqueous stability, sterility assurance, container compatibility, particulate control, and an acceptable labeled shelf life. These requirements make a ready-to-use product more complex than a lyophilized vial.

Does erythromycin lactobionate have biosimilar risk?

No. Erythromycin lactobionate is a small-molecule drug. Competitive products are generics, not biosimilars.

What is the most valuable excipient innovation for erythromycin lactobionate?

The highest practical value would likely come from a formulation that improves long-term stability and reconstitution while preserving a simple preservative-free composition. Rapid dissolution and reduced particulate formation are commercially relevant hospital benefits.

Is erythromycin lactobionate suitable for a standalone licensing transaction?

Usually not as a high-value standalone asset. Its strongest licensing potential is within a broader injectable-antibiotic portfolio, a regional hospital supply agreement, or a manufacturing partnership that uses existing sterile and lyophilization infrastructure.

References

1. U.S. Food and Drug Administration. (n.d.). Erythrocin lactobionate for injection, prescribing information.
2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Pharmacopeia. (2024). Erythromycin lactobionate and parenteral drug product standards. United States Pharmacopeial Convention.